JP2015134796A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015134796A5 JP2015134796A5 JP2015041346A JP2015041346A JP2015134796A5 JP 2015134796 A5 JP2015134796 A5 JP 2015134796A5 JP 2015041346 A JP2015041346 A JP 2015041346A JP 2015041346 A JP2015041346 A JP 2015041346A JP 2015134796 A5 JP2015134796 A5 JP 2015134796A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- cell line
- expression vector
- polynucleotide sequence
- amino acids
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 102000003812 Interleukin-15 Human genes 0.000 claims 18
- 239000002157 polynucleotide Substances 0.000 claims 10
- 102000040430 polynucleotide Human genes 0.000 claims 10
- 108091033319 polynucleotide Proteins 0.000 claims 10
- 210000004027 cell Anatomy 0.000 claims 9
- 239000013604 expression vector Substances 0.000 claims 9
- 150000001413 amino acids Chemical class 0.000 claims 6
- 239000000833 heterodimer Substances 0.000 claims 5
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 4
- 239000002773 nucleotide Substances 0.000 claims 4
- 125000003729 nucleotide group Chemical group 0.000 claims 4
- 239000008194 pharmaceutical composition Substances 0.000 claims 4
- 210000004698 lymphocyte Anatomy 0.000 claims 2
- 102000004556 Interleukin-15 Receptors Human genes 0.000 claims 1
- 108010017535 Interleukin-15 Receptors Proteins 0.000 claims 1
- 206010025327 Lymphopenia Diseases 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- 108020001507 fusion proteins Proteins 0.000 claims 1
- 102000037865 fusion proteins Human genes 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 231100001023 lymphopenia Toxicity 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 230000002093 peripheral effect Effects 0.000 claims 1
- 230000001737 promoting effect Effects 0.000 claims 1
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US23415509P | 2009-08-14 | 2009-08-14 | |
| US23415209P | 2009-08-14 | 2009-08-14 | |
| US61/234,155 | 2009-08-14 | ||
| US61/234,152 | 2009-08-14 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012524911A Division JP2013501817A (ja) | 2009-08-14 | 2010-08-13 | 胸腺産出の増大およびリンパ球減少症の治療のためのｉｌ−１５の使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015134796A JP2015134796A (ja) | 2015-07-27 |
| JP2015134796A5 true JP2015134796A5 (enExample) | 2015-09-03 |
| JP6162167B2 JP6162167B2 (ja) | 2017-07-12 |
Family
ID=42813425
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012524911A Pending JP2013501817A (ja) | 2009-08-14 | 2010-08-13 | 胸腺産出の増大およびリンパ球減少症の治療のためのｉｌ−１５の使用 |
| JP2015041346A Active JP6162167B2 (ja) | 2009-08-14 | 2015-03-03 | 胸腺産出の増大およびリンパ球減少症の治療のためのｉｌ−１５の使用 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012524911A Pending JP2013501817A (ja) | 2009-08-14 | 2010-08-13 | 胸腺産出の増大およびリンパ球減少症の治療のためのｉｌ−１５の使用 |
Country Status (8)
| Country | Link |
|---|---|
| US (5) | US8871191B2 (enExample) |
| EP (2) | EP2464377B1 (enExample) |
| JP (2) | JP2013501817A (enExample) |
| AU (2) | AU2010282280B2 (enExample) |
| CA (1) | CA2768965C (enExample) |
| ES (1) | ES2598005T3 (enExample) |
| NZ (1) | NZ714757A (enExample) |
| WO (1) | WO2011020047A1 (enExample) |
Families Citing this family (96)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT1899364T (pt) | 2005-05-17 | 2020-05-20 | Univ Connecticut | Composições e métodos para imunomodulação num organismo |
| ES2668464T3 (es) | 2005-12-02 | 2018-05-18 | Icahn School Of Medicine At Mount Sinai | Virus quiméricos de la enfermedad de Newcastle que presentan proteínas de superficie no naturales y sus usos |
| MX357691B (es) | 2006-01-13 | 2018-07-19 | The Government Of The United States As Represented By The Secretary Of The Department Of Health And | Il-15 y il-15r-alfa mejoradas para expresion en celulas mamiferas. |
| JP2010531878A (ja) | 2007-06-27 | 2010-09-30 | マリン ポリマー テクノロジーズ，インコーポレーテッド | ＩＬ‐１５とＩＬ‐１５Ｒαとの複合体及びその使用 |
| NZ714757A (en) * | 2009-08-14 | 2018-07-27 | Us Gov Health & Human Services | Use of il-15 to increase thymic output and to treat lymphopenia |
| ES2747997T3 (es) * | 2012-10-24 | 2020-03-12 | Novartis Ag | Formas de IL-15R alfa, células que expresan formas de IL-15R alfa, y usos terapéuticos de IL-15R alfa y complejos IL-15/IL-15R alfa |
| MX375431B (es) | 2013-03-14 | 2025-03-06 | Icahn School Med Mount Sinai | Virus de la enfermedad de newcastle y usos de los mismos. |
| TWI654206B (zh) | 2013-03-16 | 2019-03-21 | 諾華公司 | 使用人類化抗－ｃｄ１９嵌合抗原受體治療癌症 |
| HUE057598T2 (hu) | 2013-08-08 | 2022-05-28 | Cytune Pharma | IL-15 és IL-15R-alfa sushi domén alapú modulokinek |
| SI3094351T1 (sl) * | 2014-01-15 | 2022-05-31 | Kadmon Corporation, Llc | Imunomodulatorna sredstva |
| US20170000832A1 (en) | 2014-02-27 | 2017-01-05 | Viralytics Limited | Combination method for treatment of cancer |
| EP3593812A3 (en) | 2014-03-15 | 2020-05-27 | Novartis AG | Treatment of cancer using chimeric antigen receptor |
| KR102487608B1 (ko) | 2014-04-07 | 2023-01-12 | 노파르티스 아게 | 항-cd19 키메라 항원 수용체를 사용한 암의 치료 |
| EP3143134B1 (en) | 2014-05-15 | 2020-10-28 | National University of Singapore | Modified natural killer cells and uses thereof |
| CN107109419B (zh) | 2014-07-21 | 2020-12-22 | 诺华股份有限公司 | 使用cd33嵌合抗原受体治疗癌症 |
| RU2751660C2 (ru) | 2014-07-21 | 2021-07-15 | Новартис Аг | Лечение злокачественного новообразования с использованием гуманизированного химерного антигенного рецептора против всма |
| JP6655061B2 (ja) | 2014-07-29 | 2020-02-26 | ノバルティス アーゲー | 状態を治療するためのｉｌ−１５およびｉｌ−１５ｒアルファヘテロ二量体用量増加レジメン |
| EP3180359A1 (en) | 2014-08-14 | 2017-06-21 | Novartis AG | Treatment of cancer using gfr alpha-4 chimeric antigen receptor |
| SG11201700770PA (en) | 2014-08-19 | 2017-03-30 | Novartis Ag | Anti-cd123 chimeric antigen receptor (car) for use in cancer treatment |
| KR102804360B1 (ko) | 2014-09-17 | 2025-05-12 | 노파르티스 아게 | 입양 면역요법을 위한 키메라 수용체에 의한 세포독성 세포의 표적화 |
| US20180334490A1 (en) | 2014-12-03 | 2018-11-22 | Qilong H. Wu | Methods for b cell preconditioning in car therapy |
| CA2981751A1 (en) | 2015-04-08 | 2016-10-13 | Novartis Ag | Cd20 therapies, cd22 therapies, and combination therapies with a cd19 chimeric antigen receptor (car)- expressing cell |
| WO2016172583A1 (en) | 2015-04-23 | 2016-10-27 | Novartis Ag | Treatment of cancer using chimeric antigen receptor and protein kinase a blocker |
| US11413340B2 (en) | 2015-12-22 | 2022-08-16 | Novartis Ag | Mesothelin chimeric antigen receptor (CAR) and antibody against PD-L1 inhibitor for combined use in anticancer therapy |
| AU2017225733A1 (en) | 2016-03-04 | 2018-09-27 | Novartis Ag | Cells expressing multiple chimeric antigen receptor (CAR) molecules and uses therefore |
| JP7208010B2 (ja) | 2016-03-29 | 2023-01-18 | ユニバーシティ オブ サザン カリフォルニア | 癌を標的とするキメラ抗原受容体 |
| WO2017177063A1 (en) * | 2016-04-06 | 2017-10-12 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Use of heterodimeric il-15 in adoptive cell transfer |
| US11446398B2 (en) | 2016-04-11 | 2022-09-20 | Obsidian Therapeutics, Inc. | Regulated biocircuit systems |
| AU2017268399B2 (en) | 2016-05-18 | 2023-01-12 | Modernatx, Inc. | mRNA combination therapy for the treatment of cancer |
| CA3029813A1 (en) | 2016-06-13 | 2017-12-21 | Torque Therapeutics, Inc. | Methods and compositions for promoting immune cell function |
| WO2018013585A1 (en) * | 2016-07-12 | 2018-01-18 | Flagship Pioneering, Inc. | Methods and compositions for modulating thymic function |
| WO2018013855A2 (en) | 2016-07-14 | 2018-01-18 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Il-15/il-15 receptor alpha treatment regimens and use with therapeutic vaccines |
| CN116769050A (zh) | 2016-07-20 | 2023-09-19 | 犹他大学研究基金会 | Cd229 car t细胞及其使用方法 |
| MX2019003886A (es) | 2016-10-07 | 2019-08-05 | Novartis Ag | Receptores de antigenos quimericos para el tratamiento del cancer. |
| US10501543B2 (en) | 2016-10-14 | 2019-12-10 | Xencor, Inc. | IL15/IL15Rα heterodimeric Fc-fusion proteins |
| US11629340B2 (en) | 2017-03-03 | 2023-04-18 | Obsidian Therapeutics, Inc. | DHFR tunable protein regulation |
| CA3056630A1 (en) | 2017-03-15 | 2018-09-20 | Pandion Therapeutics, Inc. | Targeted immunotolerance |
| JP7270253B2 (ja) | 2017-03-27 | 2023-05-10 | ナショナル ユニヴァーシティ オブ シンガポール | ナチュラルキラー細胞のエクスビボ拡大及び活性化のための刺激細胞株 |
| CN117363636A (zh) | 2017-03-27 | 2024-01-09 | 新加坡国立大学 | 一种编码嵌合受体的多核苷酸 |
| AU2018256436B2 (en) | 2017-04-19 | 2024-12-05 | Board Of Regents, The University Of Texas System | Immune cells expressing engineered antigen receptors |
| US20200055948A1 (en) | 2017-04-28 | 2020-02-20 | Novartis Ag | Cells expressing a bcma-targeting chimeric antigen receptor, and combination therapy with a gamma secretase inhibitor |
| EP3615068A1 (en) | 2017-04-28 | 2020-03-04 | Novartis AG | Bcma-targeting agent, and combination therapy with a gamma secretase inhibitor |
| JOP20190256A1 (ar) | 2017-05-12 | 2019-10-28 | Icahn School Med Mount Sinai | فيروسات داء نيوكاسل واستخداماتها |
| CA3064435A1 (en) | 2017-05-24 | 2018-11-29 | Pandion Therapeutics, Inc. | Targeted immunotolerance |
| CA3064375A1 (en) | 2017-05-25 | 2018-11-29 | Memorial Sloan Kettering Cancer Center | Use of the il-15/il-15ra complex in the generation of antigen-specific t cells for adoptive immunotherapy |
| AU2018275894B2 (en) | 2017-06-02 | 2025-04-24 | Juno Therapeutics, Inc. | Articles of manufacture and methods for treatment using adoptive cell therapy |
| AU2018291032A1 (en) | 2017-06-29 | 2020-01-16 | Juno Therapeutics, Inc. | Mouse model for assessing toxicities associated with immunotherapies |
| CN111132733A (zh) | 2017-06-30 | 2020-05-08 | Xencor股份有限公司 | 含有IL-15/IL-15Rα和抗原结合结构域的靶向异源二聚体Fc融合蛋白 |
| WO2019050978A1 (en) | 2017-09-05 | 2019-03-14 | Torque Therapeutics, Inc. | THERAPEUTIC PROTEIN COMPOSITIONS AND METHODS OF PREPARATION AND USE THEREOF |
| EP3703750B1 (en) | 2017-11-01 | 2024-12-04 | Juno Therapeutics, Inc. | Chimeric antigen receptors specific for b-cell maturation antigen and encoding polynucleotides |
| CN111511370A (zh) | 2017-11-01 | 2020-08-07 | 朱诺治疗学股份有限公司 | 对b细胞成熟抗原具有特异性的抗体和嵌合抗原受体 |
| US12031975B2 (en) | 2017-11-01 | 2024-07-09 | Juno Therapeutics, Inc. | Methods of assessing or monitoring a response to a cell therapy |
| USRE50550E1 (en) | 2017-12-06 | 2025-08-26 | Pandion Operations, Inc. | IL-2 muteins and uses thereof |
| US10174092B1 (en) | 2017-12-06 | 2019-01-08 | Pandion Therapeutics, Inc. | IL-2 muteins |
| US10946068B2 (en) | 2017-12-06 | 2021-03-16 | Pandion Operations, Inc. | IL-2 muteins and uses thereof |
| WO2019118937A1 (en) | 2017-12-15 | 2019-06-20 | Juno Therapeutics, Inc. | Anti-cct5 binding molecules and methods of use thereof |
| WO2019155288A1 (en) | 2018-02-09 | 2019-08-15 | National University Of Singapore | Activating chimeric receptors and uses thereof in natural killer cell immunotherapy |
| EP3755349A4 (en) | 2018-02-21 | 2021-11-17 | Board of Regents, The University of Texas System | PROCESS FOR ACTIVATION AND EXPANSION OF NATURAL KILLER CELLS AND THEIR USES |
| SG11202008976YA (en) | 2018-04-02 | 2020-10-29 | Nat Univ Singapore | Neutralization of human cytokines with membrane-bound anti-cytokine non-signaling binders expressed in immune cells |
| AU2019256539A1 (en) | 2018-04-18 | 2020-11-26 | Xencor, Inc. | PD-1 targeted heterodimeric fusion proteins containing IL-15/IL-15Ra Fc-fusion proteins and PD-1 antigen binding domains and uses thereof |
| WO2019204655A1 (en) | 2018-04-18 | 2019-10-24 | Xencor, Inc. | Tim-3 targeted heterodimeric fusion proteins containing il-15/il-15ra fc-fusion proteins and tim-3 antigen binding domains |
| EP3781596A1 (en) | 2018-04-18 | 2021-02-24 | Xencor, Inc. | Il-15/il-15ra heterodimeric fc fusion proteins and uses thereof |
| EP3784351A1 (en) | 2018-04-27 | 2021-03-03 | Novartis AG | Car t cell therapies with enhanced efficacy |
| US20210213063A1 (en) | 2018-05-25 | 2021-07-15 | Novartis Ag | Combination therapy with chimeric antigen receptor (car) therapies |
| SG11202011830SA (en) | 2018-06-13 | 2020-12-30 | Novartis Ag | Bcma chimeric antigen receptors and uses thereof |
| WO2020037215A1 (en) | 2018-08-17 | 2020-02-20 | Icahn School Of Medicine At Mount Sinai | Recombinant newcastle disease viruses and uses thereof for the prevention of rsv disease or human metapneumovirus disease |
| JP7560882B2 (ja) | 2018-08-29 | 2024-10-03 | ナショナル ユニヴァーシティー オブ シンガポール | 遺伝子修飾免疫細胞の生存及び増加を特異的に刺激するための方法 |
| EP3856764A4 (en) | 2018-09-27 | 2022-11-02 | Xilio Development, Inc. | MASKED CYTOKINE POLYPEPTIDES |
| EP3856782A1 (en) | 2018-09-28 | 2021-08-04 | Novartis AG | Cd19 chimeric antigen receptor (car) and cd22 car combination therapies |
| EP3856779A1 (en) | 2018-09-28 | 2021-08-04 | Novartis AG | Cd22 chimeric antigen receptor (car) therapies |
| CN113423734A (zh) | 2018-10-12 | 2021-09-21 | Xencor股份有限公司 | 靶向PD-1的IL-15/IL-15RαFC融合蛋白及其在联合疗法中的应用 |
| EP3873943A2 (en) | 2018-11-01 | 2021-09-08 | Juno Therapeutics, Inc. | Methods for treatment using chimeric antigen receptors specific for b-cell maturation antigen |
| PE20211058A1 (es) | 2018-11-01 | 2021-06-07 | Juno Therapeutics Inc | Receptores de antigenos quimericos especificos para el miembro d del grupo 5 de la clase c del receptor acoplado a proteina g (gprc5d) |
| JP2022513062A (ja) | 2018-11-16 | 2022-02-07 | ジュノー セラピューティクス インコーポレイテッド | Ｂ細胞悪性腫瘍を処置するために、操作されたｔ細胞を投薬する方法 |
| KR20210117260A (ko) | 2018-11-30 | 2021-09-28 | 주노 쎄러퓨티크스 인코퍼레이티드 | 입양 세포 요법을 사용한 치료방법 |
| EP3897853A1 (en) | 2018-12-20 | 2021-10-27 | Xencor, Inc. | Targeted heterodimeric fc fusion proteins containing il-15/il-15ra and nkg2d antigen binding domains |
| WO2020146835A1 (en) * | 2019-01-11 | 2020-07-16 | Memorial Sloan Kettering Cancer Center | Multimerization of il-15/il-15r-alpha-fc complexes to enhance immunotherapy |
| CN113365660A (zh) | 2019-01-29 | 2021-09-07 | 朱诺治疗学股份有限公司 | 对受体酪氨酸激酶样孤儿受体1(ror1)具特异性的抗体及嵌合抗原受体 |
| BR112021017537A2 (pt) | 2019-03-05 | 2021-12-14 | Nkarta Inc | Receptores de antígeno quimérico dirigidos a cd19 e usos dos mesmos em imunoterapia |
| CN113811603B (zh) * | 2019-03-15 | 2024-08-16 | 河谷细胞有限公司 | 重组erIL-15 NK细胞 |
| BR112021023345A2 (pt) | 2019-05-20 | 2022-02-01 | Pandion Operations Inc | Imunotolerância com alvo em madcam |
| US20220332780A1 (en) | 2019-09-10 | 2022-10-20 | Obsidian Therapeutics, Inc. | Ca2-il15 fusion proteins for tunable regulation |
| TW202128757A (zh) | 2019-10-11 | 2021-08-01 | 美商建南德克公司 | 具有改善之特性的 PD-1 標靶 IL-15/IL-15Rα FC 融合蛋白 |
| WO2021168079A1 (en) | 2020-02-21 | 2021-08-26 | Pandion Operations, Inc. | Tissue targeted immunotolerance with a cd39 effector |
| AU2021251265A1 (en) | 2020-04-10 | 2022-11-03 | Juno Therapeutics, Inc. | Methods and uses related to cell therapy engineered with a chimeric antigen receptor targeting B-cell maturation antigen |
| AU2021378316A1 (en) | 2020-11-13 | 2023-06-01 | Novartis Ag | Combination therapies with chimeric antigen receptor (car)-expressing cells |
| CA3196844A1 (en) | 2020-11-25 | 2022-06-02 | Raphael Rozenfeld | Tumor-specific cleavable linkers |
| US12234473B2 (en) | 2020-12-31 | 2025-02-25 | Immatics US, Inc. | CD8 polypeptides, compositions, and methods of using thereof |
| WO2023086772A1 (en) | 2021-11-12 | 2023-05-19 | Xencor, Inc. | Bispecific antibodies that bind to b7h3 and nkg2d |
| US20250332180A1 (en) * | 2022-05-17 | 2025-10-30 | The Regents Of The University Of California | Cannabinoids and il-15 activate nk cells |
| WO2023250400A1 (en) | 2022-06-22 | 2023-12-28 | Juno Therapeutics, Inc. | Treatment methods for second line therapy of cd19-targeted car t cells |
| CA3263560A1 (en) | 2022-08-05 | 2024-02-08 | Juno Therapeutics Inc | GPRC5D AND BCMA SPECIFIC CHIMERICAL ANTIGENIC RECEPTORS |
| EP4572781A2 (en) | 2022-08-16 | 2025-06-25 | The United States of America, as Represented By the Secretary, Department of Health and Human Services | Synergistic interactions for improved cancer treatment |
| WO2024102636A1 (en) | 2022-11-07 | 2024-05-16 | Xencor, Inc. | Bispecific antibodies that bind to b7h3 and mica/b |
| AR131320A1 (es) | 2022-12-13 | 2025-03-05 | Juno Therapeutics Inc | Receptores de antígenos quiméricos específicos para baff-r y cd19 y métodos y usos de los mismos |
| US20250243279A1 (en) | 2023-10-17 | 2025-07-31 | Xencor, Inc. | Bispecific antibodies that bind to nkp46 and mica/b |
Family Cites Families (54)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK0417563T3 (da) | 1989-09-12 | 2000-11-06 | Hoffmann La Roche | TNF-bindende proteiner |
| ATE311895T1 (de) | 1992-05-26 | 2005-12-15 | Immunex Corp | Neue zytokine die cd30 binden |
| US5574138A (en) | 1993-03-08 | 1996-11-12 | Immunex Corporation | Epithelium-derived T-cell factor |
| US5552303A (en) | 1993-03-08 | 1996-09-03 | Immunex Corporation | DNA encoding epithelium-derived T-cell factor |
| US6063911A (en) | 1993-12-01 | 2000-05-16 | Marine Polymer Technologies, Inc. | Methods and compositions for treatment of cell proliferative disorders |
| US5858350A (en) | 1993-12-01 | 1999-01-12 | Marine Polymer Technologies | Methods and compositions for poly-β-1→4-N-acetylglucosamine cell therapy system |
| DK0772624T3 (da) | 1994-04-06 | 2000-11-13 | Immunex Corp | Interleukin-15 |
| US5591630A (en) | 1994-05-06 | 1997-01-07 | Immunex Corporation | Monoclonal antibodies that bind interleukin-15 receptors |
| US6548065B1 (en) | 1994-05-06 | 2003-04-15 | Immunex Corporation | Interleukin-15 receptors |
| US20020127201A1 (en) | 1994-07-01 | 2002-09-12 | Dana-Farber Cancer Institute. | Methods for inhibiting T cell responses by manipulating a common cytokine receptor gamma-chain |
| US7008624B1 (en) | 1995-02-22 | 2006-03-07 | Immunex Corporation | Antagonists of interleukin-15 |
| US5660824A (en) | 1995-05-24 | 1997-08-26 | Grabstein; Kenneth H. | Muscle trophic factor |
| US6369027B1 (en) | 1995-12-22 | 2002-04-09 | Amgen Inc. | Osteoprotegerin |
| DE19608813C2 (de) | 1996-03-07 | 1998-07-02 | Angewandte Gentechnologie Syst | Konjugat zur Beeinflussung von Wechselwirkungen zwischen Proteinen |
| CA2252557A1 (en) | 1996-04-26 | 1997-11-06 | Beth Israel Deaconess Medical Center, Inc. | Antagonists of interleukin-15 |
| US6451308B1 (en) | 1996-04-26 | 2002-09-17 | Beth Israel Deaconess Medical Center | Antagonists of interleukin-15 |
| NZ514145A (en) | 1996-12-20 | 2003-08-29 | Amgen Inc | OB fusion protein compositions and methods |
| US6344192B1 (en) | 1997-02-21 | 2002-02-05 | Vlaams Interuniversitair Instituut Voor Biotechnologie | Use of interleukin-15 |
| US6787132B1 (en) | 1997-12-04 | 2004-09-07 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Combined chemo-immunotherapy with liposomal drugs and cytokines |
| US20040170604A1 (en) | 1998-07-06 | 2004-09-02 | Tosoh Corporation | IL-6 receptor IL-6 direct fusion protein |
| GB9814892D0 (en) | 1998-07-10 | 1998-09-09 | Kennedy Rheumatology Inst | Treatment of celiac disease |
| US20050202005A1 (en) | 1998-07-31 | 2005-09-15 | The Trustees Of Columbia University In The City Of New York | Uses of inhibitors for the activation of CXCR4 receptor by SDF-1 in treating rheumatoid arthritis |
| US6946465B2 (en) | 1999-02-02 | 2005-09-20 | 4 Aza Bioscience Nv | Immunosuppressive effects of pteridine derivatives |
| US20010046486A1 (en) | 2000-04-17 | 2001-11-29 | Boyd Richard L. | Stimulation of thymus for vaccination development |
| WO2000062805A1 (en) | 1999-04-15 | 2000-10-26 | Duke University | A method of reversing thymic atrophy |
| CA2379388C (en) | 1999-07-13 | 2012-05-29 | George N. Cox, Iii | Immunoglobulin fusion proteins |
| AU2001259253A1 (en) | 2000-04-26 | 2001-11-07 | National Jewish Medical And Research Center | Product and process for regulation of t cell responses |
| JP2003533488A (ja) | 2000-05-12 | 2003-11-11 | ベス・イスラエル・ディーコニス・メディカル・センター・インコーポレーテッド | 免疫抑制を達成するための組成物および方法 |
| IL154925A0 (en) | 2000-09-14 | 2003-10-31 | Beth Israel Hospital | Modulation of il-2 and il-15-mediated t cell responses |
| JP2004517817A (ja) * | 2000-10-13 | 2004-06-17 | モナッシュ ユニバーシティ | 胸腺を再活性化することによる疾患の予防 |
| EP1363703A4 (en) | 2000-10-13 | 2006-06-07 | Univ Monash | PREVENTION OF DISEASES BY REACTIVATION OF THYMUS |
| US7638604B2 (en) | 2001-02-23 | 2009-12-29 | Genetics Institute, Llc | Monoclonal antibodies against interleukin-22 |
| JP2003169693A (ja) * | 2001-12-07 | 2003-06-17 | Japan Energy Corp | 可溶性ＩＬ−１５レセプターα鎖の製造方法 |
| US7217798B2 (en) | 2003-10-15 | 2007-05-15 | Pdl Biopharma, Inc. | Alteration of Fc-fusion protein serum half-lives by mutagenesis |
| WO2004058278A1 (en) | 2002-12-16 | 2004-07-15 | The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Recombinant vaccine viruses expressing il-15 and methods of using the same |
| DE10260805A1 (de) | 2002-12-23 | 2004-07-22 | Geneart Gmbh | Verfahren und Vorrichtung zum Optimieren einer Nucleotidsequenz zur Expression eines Proteins |
| JPWO2005023289A1 (ja) | 2003-09-08 | 2007-11-01 | 株式会社インテレクチャル・プロパティ・コンサルティング | 慢性ｃ型肝炎を治療するための医薬組成物 |
| US7435596B2 (en) | 2004-11-04 | 2008-10-14 | St. Jude Children's Research Hospital, Inc. | Modified cell line and method for expansion of NK cell |
| WO2005085282A1 (en) | 2004-02-27 | 2005-09-15 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | Il-15 binding site for il15-ralpha and specific il-15 mutants having agonists/antagonists activity |
| WO2006017853A2 (en) | 2004-08-11 | 2006-02-16 | Beth Israel Deaconess Medical Center, Inc. | Mutant interleukin-15-containing compositions and suppression of an immune response |
| CA2583274A1 (en) | 2004-10-05 | 2007-02-15 | Ochsner Clinic Foundation | Enhancement of b cell proliferation by il-15 |
| US20060165668A1 (en) | 2004-12-10 | 2006-07-27 | Liu Linda N | Genetically modified tumor cells as cancer vaccines |
| US20060257361A1 (en) * | 2005-04-12 | 2006-11-16 | Government Of The Us, As Represented By The Secretary, Department Of Health And Human Services | Novel form of interleukin-15, Fc-IL-15, and methods of use |
| PT1899364T (pt) * | 2005-05-17 | 2020-05-20 | Univ Connecticut | Composições e métodos para imunomodulação num organismo |
| EP1777294A1 (en) | 2005-10-20 | 2007-04-25 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | IL-15Ralpha sushi domain as a selective and potent enhancer of IL-15 action through IL-15Rbeta/gamma, and hyperagonist (IL15Ralpha sushi -IL15) fusion proteins |
| US20070160578A1 (en) * | 2005-12-14 | 2007-07-12 | The Gov. Of The Usa As Represented By The Secretary Of The Dep. Of Health And Human Services | Expansion of natural killer and CD8 T-cells with IL-15R/ligand activator complexes |
| MX357691B (es) * | 2006-01-13 | 2018-07-19 | The Government Of The United States As Represented By The Secretary Of The Department Of Health And | Il-15 y il-15r-alfa mejoradas para expresion en celulas mamiferas. |
| JP4886304B2 (ja) | 2006-01-27 | 2012-02-29 | 昭和シェル石油株式会社 | グリース組成物 |
| EP1987065A4 (en) | 2006-02-16 | 2010-01-20 | Nascent Biolog Inc | METHOD FOR IMPROVING THE IMMUNE FUNCTION AND METHOD FOR PREVENTING OR TREATING DISEASES IN MAMMALS |
| NZ575571A (en) | 2006-10-04 | 2011-11-25 | Janssen Pharmaceutica Nv | Preparation of inactivated artificial antigen presenting cells and their use in cell therapies |
| WO2008089144A2 (en) | 2007-01-12 | 2008-07-24 | The Government Of The United States, As Represented By The Secretary Of Health And Human Services | Improved dna vaccination protocols |
| AU2008253720B2 (en) | 2007-05-11 | 2014-01-16 | Altor Bioscience Corporation | Fusion molecules and IL-15 variants |
| JP2010531878A (ja) | 2007-06-27 | 2010-09-30 | マリン ポリマー テクノロジーズ，インコーポレーテッド | ＩＬ‐１５とＩＬ‐１５Ｒαとの複合体及びその使用 |
| NZ714757A (en) * | 2009-08-14 | 2018-07-27 | Us Gov Health & Human Services | Use of il-15 to increase thymic output and to treat lymphopenia |
-
2010
- 2010-08-13 NZ NZ714757A patent/NZ714757A/en unknown
- 2010-08-13 CA CA2768965A patent/CA2768965C/en active Active
- 2010-08-13 ES ES10752466.2T patent/ES2598005T3/es active Active
- 2010-08-13 WO PCT/US2010/045511 patent/WO2011020047A1/en not_active Ceased
- 2010-08-13 AU AU2010282280A patent/AU2010282280B2/en active Active
- 2010-08-13 EP EP10752466.2A patent/EP2464377B1/en active Active
- 2010-08-13 US US13/390,504 patent/US8871191B2/en active Active
- 2010-08-13 JP JP2012524911A patent/JP2013501817A/ja active Pending
- 2010-08-13 EP EP16174632.6A patent/EP3135294B1/en active Active
-
2014
- 2014-10-13 US US14/512,913 patent/US9975937B2/en active Active
-
2015
- 2015-03-03 JP JP2015041346A patent/JP6162167B2/ja active Active
-
2016
- 2016-05-23 AU AU2016203362A patent/AU2016203362B2/en active Active
-
2017
- 2017-04-11 US US15/485,093 patent/US10093710B2/en active Active
-
2018
- 2018-05-02 US US15/969,647 patent/US10894816B2/en active Active
- 2018-09-06 US US16/123,431 patent/US11041008B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015134796A5 (enExample) | ||
| NZ628126A (en) | Histidyl-trna synthetases for treating autoimmune and inflammatory diseases | |
| EA201692359A1 (ru) | Композиция на основе нового штамма prrsv или его белков, продукт, их применение, вирус prrsv, выделенная нк и рекомбинантный вектор экспрессии для получения этого вируса | |
| NZ602943A (en) | Modified binding proteins inhibiting the vegf-a receptor interaction | |
| TN2012000393A1 (en) | Agonist dr5 binding polypeptides | |
| WO2013151672A3 (en) | Modified polynucleotides for the production of oncology-related proteins and peptides | |
| TN2012000372A1 (en) | Fibronectin based scaffold domain proteins that bind il-23 | |
| NZ604818A (en) | Variants of activin iib receptor polypeptides and uses thereof | |
| NZ616989A (en) | Therapeutic nuclease compositions and methods | |
| EP3412304A3 (en) | Hla-a24 agonist epitopes of muc1-c oncoprotein and compositions and methods of use | |
| RU2015119517A (ru) | Новый способ лечения инфаркта миокарда с применением фрагмента hmgb1 | |
| JP2017006120A5 (enExample) | ||
| JP2015514132A5 (enExample) | ||
| IN2014DN06920A (enExample) | ||
| MX2009000659A (es) | Composiciones de polipeptidos de retrovirus endogeno humano y metodo para su uso. | |
| NZ602845A (en) | Inhibiting peptides derived from trem-like transcript 1 (tlt-1) and uses thereof | |
| JP2012529293A5 (enExample) | ||
| UA100127C2 (ru) | Пептид cdh3 и лекарственное средство, содержащее его | |
| JP2014529399A5 (enExample) | ||
| NZ705899A (en) | Inhibiting peptides derived from triggering receptor expressed on myeloid cells-1 (trem-1) trem-like transcript 1 (tlt-1) and uses thereof | |
| IN2014DN09963A (enExample) | ||
| SI2718434T1 (en) | Compounds and procedures for the treatment of celiac disease | |
| NZ610620A (en) | Inhibitors of apoptosis and uses thereof | |
| RU2015119523A (ru) | Новый способ лечения повреждения спинного мозга с применением фрагмента hmgb1 | |
| IL269187B2 (en) | Dominant active yap, a hippo effector, induces chromatin accessiblity and cardiomyocyte renewal |